儿童静脉血栓栓塞症抗凝疗程:儿童血栓形成治疗疗程评估(Kids-DOTT)试验2年结局
Kids-DOTT多国随机临床试验纳入21岁以下诱发性静脉血栓栓塞症患者,6周抗凝与3个月抗凝在1年净临床获益上非劣效。本研究报告2年随访结果,意向治疗人群(n=417)中6周组与3个月组症状性复发性VTE累积发生率分别为1.7%和2.9%,临床相关出血分别为1.1%和3.2%,双变量分析显示6周抗凝对3个月疗程非劣效。
要点
- 6周抗凝与3个月抗凝在2年净临床获益上非劣效。
- 6周组症状性复发性VTE 2年累积发生率1.7%,3个月组2.9%。
- 6周组临床相关出血2年累积发生率1.1%,3个月组3.2%。
核心结论
- 这些发现支持Kids-DOTT随机临床试验1年净临床获益结果在2年时的持久性。
研究设计与样本
- 多中心、多国、随机临床试验,纳入21岁以下诱发性静脉血栓栓塞症患者。
- VTE诊断后6周重复影像未显示完全静脉闭塞的患者随机分配至停止抗凝组或接受总共3个月疗程组,随访2年。
- 意向治疗人群n=417,结局由中心裁定,采用预设双变量非劣效边界比较净临床获益。
主要发现
- 意向治疗人群2年累积发生率:6周组症状性复发性VTE 1.7%(95%CI 0%~3.7%),3个月组2.9%(95%CI 0.3%~5.4%)。
- 意向治疗人群2年累积发生率:6周组临床相关出血1.1%(95%CI 0%~2.5%),3个月组3.2%(95%CI 0.6%~5.7%)。
- 意向治疗人群绝对风险差异的双变量分析显示,6周抗凝疗程对3个月疗程非劣效。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Multicenter Evaluation of the Duration of Therapy for Thrombosis in Children multinational, randomized clinical trial revealed noninferiority of a 6-week vs 3-month duration of anticoagulation for the treatment of provoked venous thromboembolism (VTE) in patients <21 years old in regard to net clinical benefit at 1 year. OBJECTIVES: To evaluate noninferiority at 2 years. METHODS: Patients whose repeat imaging 6 weeks after VTE diagnosis did not show complete veno-occlusion were randomized to discontinue anticoagulation vs receive a total 3-month course and followed for 2 years for the occurrence of symptomatic recurrent VTE (efficacy outcome) and clinically relevant bleeding (safety outcome). Outcomes were centrally adjudicated, and net clinical benefit was compared between treatment arms via a prespecified bivariate noninferiority boundary, using 95% CIs in absolute risk differences between treatment arms. RESULTS: Kaplan-Meier estimates of 2-year cumulative incidences in the 6-week and 3-month arms of the intention-to-treat population (n = 417) were 1.7% (95% CI, 0%, 3.7%) and 2.9% (95% CI, 0.3%, 5.4%), respectively, for symptomatic recurrent VTE and 1.1% (95% CI, 0%, 2.5%) and 3.2% (95% CI, 0.6%, 5.7%), respectively, for clinically relevant bleeding. Bivariate analysis of the absolute risk differences in the intention-to-treat population demonstrated that a 6-week anticoagulation duration was noninferior to a 3-month course. CONCLUSION: These findings support durability of the Kids-DOTT randomized clinical trial findings of net clinical benefit at 2 years.
引用
- Goldenberg NA, Schulman S, Kittelson JM, et al. Duration of anticoagulation for venous thromboembolism in pediatric patients: Evaluation of the Duration of Therapy for Thrombosis in Children (Kids-DOTT) trial outcomes at 2 years. J Thromb Haemost. 2024. PMID: 39461724. doi:10.1016/j.jtha.2024.09.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。